The CRUK KHP Centre is directed at discovering how tumour progression is shaped by the component cells of the tumour microenvironment or Tumour Metropolis (Theme 1). Our goal is to provide transformative knowledge of heterotypic interactions that underpin the frequent failure of approved therapies, but themselves offer opportunities for the development of new therapies.
The Metropolis is accessible to state-of-the-art Profiling and Imaging (Theme 3), where we have expertise ranging from genetics and immunophenotyping to optical proteomics (FRET/FLIM platform) and whole-patient imaging.
Our Immune biotherapies development programme (Theme 2), is predicated on deepening our understanding of how the tumour re-programmes and corrupts the cellular and molecular Tumour Metropolis. Taking a functional view of the survival and evasive behaviours of the tumour provides the foundations for new interventions. We apply a multi-platform biotherapies capability aligned with the mode of action desired.